-
EP1658859
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP1658859
| EP1658859 - APO-2L receptor agonist and CPT-11 synergism [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 02.03.2012 Database last updated on 19.10.2024 | Most recent event Tooltip | 02.03.2012 | Application deemed to be withdrawn | published on 04.04.2012 [2012/14] | Applicant(s) | For all designated states Genentech, Inc. 1 DNA Way South San Francisco, CA 94080-4990 / US | [N/P] |
| Former [2008/38] | For all designated states Genentech, Inc. 1 DNA Way South San Francisco CA 94080-4990 / US | ||
| Former [2006/21] | For all designated states GENENTECH, INC. 1 DNA Way South San Francisco California 94080 / US | Inventor(s) | 01 /
Ashkenzai, Avi. J. 1456 Tarrytown Street San Mateo, CA 94402 / US | 02 /
Benyunes, Mark C. 620 Belvedere Street San Francisco, CA 94117 / US | 03 /
Schwall, Ralph H. 400 Griffin Avenue Pacifica, CA 94044 / US | [2006/21] | Representative(s) | Kiddle, Simon John, et al Mewburn Ellis LLP City Tower 40 Basinghall Street London EC2V 5DE / GB | [N/P] |
| Former [2006/21] | Kiddle, Simon John, et al Mewburn Ellis LLP York House, 23 Kingsway London WC2B 6HP / GB | Application number, filing date | 06003358.6 | 07.06.2000 | [2006/21] | Priority number, date | US19990138240P | 09.06.1999 Original published format: US 138240 P | [2006/21] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP1658859 | Date: | 24.05.2006 | Language: | EN | [2006/21] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 05.04.2006 | Classification | IPC: | A61K39/395, A61K31/47, // A61K39/395, A61K31/47, C07K16/28 | [2006/21] | CPC: |
C07K16/2878 (EP);
A61K39/39541 (EP);
A61K2039/505 (EP);
C07K2317/73 (EP)
| C-Set: |
A61K39/39541, A61K2300/00 (EP)
| Designated contracting states | AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE [2006/21] | Title | German: | APO-2L Rezeptor-Agonist und CPT-11 Synergie-Effekt | [2006/21] | English: | APO-2L receptor agonist and CPT-11 synergism | [2006/21] | French: | Synergie des agonistes du récepteur APO-2L et du CPT-11 | [2006/21] | Biological material | This application mentions deposited biological material, check the file for details | Examination procedure | 06.03.2006 | Examination requested [2006/21] | 14.12.2006 | Despatch of a communication from the examining division (Time limit: M06) | 05.10.2007 | Reply to a communication from the examining division | 02.06.2009 | Despatch of a communication from the examining division (Time limit: M02) | 21.07.2009 | Reply to a communication from the examining division | 06.06.2011 | Communication of intention to grant the patent | 18.10.2011 | Application deemed to be withdrawn, date of legal effect [2012/14] | 18.11.2011 | Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time [2012/14] | Parent application(s) Tooltip | EP00941233.9 / EP1192185 | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20000941233) is 16.07.2003 | Request for further processing for: | 05.10.2007 | Request for further processing filed | 05.10.2007 | Full payment received (date of receipt of payment) Request granted | 19.10.2007 | Decision despatched | Fees paid | Renewal fee | 06.03.2006 | Renewal fee patent year 03 | 06.03.2006 | Renewal fee patent year 04 | 06.03.2006 | Renewal fee patent year 05 | 06.03.2006 | Renewal fee patent year 06 | 25.08.2006 | Renewal fee patent year 07 | 14.06.2007 | Renewal fee patent year 08 | 28.03.2008 | Renewal fee patent year 09 | 16.06.2009 | Renewal fee patent year 10 | 11.06.2010 | Renewal fee patent year 11 | 13.06.2011 | Renewal fee patent year 12 | Penalty fee | Additional fee for renewal fee | 30.06.2006 | 07 M06 Fee paid on 25.08.2006 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [AD]WO9725428 (GENENTECH INC [US]) [AD] 1-18 * page 35 - page 41; examples 4-12 *; | [PA]WO9937684 (GENENTECH INC [US]) [PA] 1-18* page 23 - page 27; examples 1-6 *; | [A] - SCHILLER, JOAN H., "Topotecan in small-cell lung cancer", SEMIN. ONCOL. (1997), 24(6, SUPPL. 20), S20/27-S20/33, (1997), XP000973356 [A] 1-18 * the whole document * | [AD] - PAN, GUOHUA ET AL, "The receptor for the cytotoxic ligand TRAIL", SCIENCE (WASHINGTON, D. C.) (1997), 276(5309), 111 - 113, (1997), XP002158405 [AD] 1-18 * the whole document * DOI: http://dx.doi.org/10.1126/science.276.5309.111 | [PA] - ASHKENAZI A ET AL, "Safety and antitumor activity of recombinant soluble Apo2 ligand.", JOURNAL OF CLINICAL INVESTIGATION, (1999 JUL) 104 (2) 155-62., (1999), XP000973369 [PA] 1-18 * page 155 * * page 161 - page 162, column L * DOI: http://dx.doi.org/10.1172/JCI6926 | by applicant | - SCHOLTISSEK ET AL., GENE, (1988), vol. 62, pages 55 - 64 |